BMEZ vs QCRH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 1/9, indicating weak fundamental strength. The absence of an Altman Z-Score and all profitability metrics at 0.00% suggest opaque or non-existent earnings power and potential structural risks. Despite a high dividend yield of 8.49%, the unsustainable 846.82% payout ratio and bearish insider activity raise red flags. Combined with negative long-term price performance and lack of analyst coverage, the investment case lacks foundational support.
QCRH exhibits a stable financial profile with a Piotroski F-Score of 4/9 and is currently undervalued, trading at $92.77, well below its Graham Number of $105.98 and Intrinsic Value of $220.96. The company demonstrates exceptional operational consistency, having beaten earnings estimates in nearly every quarter over the last 25 reporting periods. While technical trends and insider sentiment are currently bearish, the strong YoY revenue (17.10%) and earnings growth (19.40%) provide a powerful fundamental cushion. The valuation suggests a significant margin of safety for long-term investors.
Compare Another Pair
Related Comparisons
BMEZ vs QCRH: Head-to-Head Comparison
This page compares BlackRock Health Sciences Term Trust (BMEZ) and QCR Holdings, Inc. (QCRH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.